Sanare Lab LTD – Trademark Portfolio

Entity Type: 99

Sanare Lab LTD holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 6 trademarks are registered and 11 are pending. Notable registered marks include IVERMK6, 2THELIFE, IVERMK12, FENZOLE222, and FENZOLE444. The owner is based in London.

128 City Road

London EC1V2NX , GB

18 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Sanare Lab LTD's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (16 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Sanare Lab LTD have?

Sanare Lab LTD has 18 U.S. trademarks filed with the USPTO. Of these, 6 registered, 11 pending, 1 abandoned.

What trademark classes does Sanare Lab LTD file in?

Sanare Lab LTD files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Sanare Lab LTD's most well-known trademarks?

Sanare Lab LTD's registered trademark portfolio includes well-known marks such as IVERMK6, 2THELIFE, IVERMK12, FENZOLE222, and FENZOLE444. These are among 6 currently registered trademarks in the portfolio.

What is Sanare Lab LTD's trademark registration success rate?

Sanare Lab LTD has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 11 applications are pending review.